These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 17594389

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
    DeFronzo RA.
    Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
    Lupi R, Del Prato S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587
    [Abstract] [Full Text] [Related]

  • 8. beta-cell function and anti-diabetic pharmacotherapy.
    Del Prato S, Bianchi C, Marchetti P.
    Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [Abstract] [Full Text] [Related]

  • 12. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm.
    Green J, Feinglos M.
    Int J Clin Pract Suppl; 2007 Aug; (154):3-11. PubMed ID: 17593272
    [Abstract] [Full Text] [Related]

  • 13. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK, Suffoletta TJ, Jennings HR.
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [Abstract] [Full Text] [Related]

  • 14. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
    Panina G.
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 19. Preservation of beta-cell function by targeting beta-cell mass.
    de Koning EJ, Bonner-Weir S, Rabelink TJ.
    Trends Pharmacol Sci; 2008 Apr; 29(4):218-27. PubMed ID: 18359095
    [Abstract] [Full Text] [Related]

  • 20. Reflecting on type 2 diabetes prevention: more questions than answers!
    Rosenstock J.
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.